The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Drug Resistance In DNA Repair Defective Ovarian Cancer
Funder
National Health and Medical Research Council
Funding Amount
$122,032.00
Summary
Ovarian cancer is a major cause of cancer death in women because current treatments are inadequate. Half of aggressive ovarian cancers have abnormalities in DNA repair and respond to new PARP inhibitor therapy, yet even then the cancer often recurs. I will use a new model to study human ovarian cancers in mice. My focus will be understanding resistance to PARP inhibitors in individual ovarian cancers and designing approaches to overcome this resistance.
Studies On New Mononuclear And Polynuclear Platinum Compounds With Trans-geometry
Funder
National Health and Medical Research Council
Funding Amount
$68,617.00
Summary
Even in post-genomic age cisplatin continues to be widely used as a highly successful anticancer drug. However, the drug has a number of side effects and does not show activity against many types of cancer. in some cases, resistant form of cancer develops for which the drug does not function. An example is ovarian cancer. This project aims to arrive at new platinum-based anticancer drugs targeted to ovarian cancer.
Could Pharmacological Restoration Of Mecp2 Levels Be Of Therapeutic Value In Rett Syndrome?
Funder
National Health and Medical Research Council
Summary
Rett syndrome is one of the commonest single gene cause of developmental disability in girls; 1:8500 Australian females are affected by the age of 12. There is currently no cure. Rett syndrome most commonly results from a fault in one copy of the Mecp2 gene on the X chromosome. The proposed research aims to identify medicines, already known to be safe in children and adults, which specifically improve the functioning of the Mecp2 gene. This should rapidly lead to targeted clinical treatments for ....Rett syndrome is one of the commonest single gene cause of developmental disability in girls; 1:8500 Australian females are affected by the age of 12. There is currently no cure. Rett syndrome most commonly results from a fault in one copy of the Mecp2 gene on the X chromosome. The proposed research aims to identify medicines, already known to be safe in children and adults, which specifically improve the functioning of the Mecp2 gene. This should rapidly lead to targeted clinical treatments for this condition.Read moreRead less
Designing Novel Apolipoprotein A1 Mimetic Peptides As Drug Treatment For Atherosclerosis
Funder
National Health and Medical Research Council
Funding Amount
$60,016.00
Summary
Cardiovascular disease is the formation of atherosclerotic plaques caused by the imbalance between the amount of cholesterol delivered and removed from the arteries. Apolipoprotein A-1 (ApoA-1) is the main protein of high density lipoprotein (HDL) and removes cholesterol out of cell. In this project we are aimed at designing and testing new drugs (ApoA1-mimetic peptides) which will elicit the same anti-atherogenic properties as apoA-1, as a therapeutic agent for prevention of atherosclerosis.